Table 3.
Age, race, and sex adjusted risk ratios for the associations between discharge to long-term care and medication use among REGARDS participants hospitalized for HFrEF
| Admission medication lista | Discharge medication lista | Claims within 1 yearb | |
|---|---|---|---|
| Beta-blocker | 1.1 (0.9, 1.4) | 1.2 (1.0, 1.4) | 1.0 (0.7, 1.4) |
| HFrEF beta-blockerc | 1.0 (0.6, 1.7) | 1.3 (0.9, 1.9) | 1.0 (0.6, 1.8) |
| ACEI/ARB | 1.0 (0.6, 1.6) | 1.0 (0.6, 1.6) | 1.0 (0.6, 1.7) |
| Any diuretic | 1.1 (0.8, 1.4) | 1.0 (0.8, 1.2) | 0.7 (0.4, 1.1) |
| Loop diuretic | 1.2 (0.9, 1.6) | 1.0 (0.8, 1.2) | 0.7 (0.4, 1.1) |
| Aldosterone receptor antagonist | 0.6 (0.1, 2.3) | 0.7 (0.2, 2.2) | 0.2 (0.0, 1.4) |
| Hydralazine in combination with isosorbide dinitrate | 0.9 (0.2, 3.7) | 0.2 (0.0, 1.3) | 0.2 (0.0, 1.8) |
HFrEF Heart failure with reduced ejection fraction, ACEI/ARB Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
aDetermined from review of medical records
bDetermined using Medicare claims data
cCarvedilol, metoprolol succinate, or bisoprolol